Frontier Medicines Announces Publication in Structure Highlighting Novel E3 Ligase DCAF2 can be Harnessed for Targeted Protein Degradation
- First report of high-resolution structures of DCAF2 -
- Frontier™ Platform key to discovering covalent ligands to selectively target DCAF2 -
BOSTON and SOUTH SAN FRANCISCO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical-stage precision medicine company unlocking the proteome to develop small molecule drugs against previously undruggable disease-causing targets, today announced the publication of groundbreaking discoveries in Structure, a Cell Press journal, demonstrating that DCAF2 can be harnessed as a novel E3 ligase for targeted protein degradation (TPD). DCAF2 presents an exciting opportunity to deliver tumor-targeted protein degraders given its frequent overexpression in various types of cancer. In addition, this work expands the small repertoire of E3 ligases that can be used to degrade proteins, offering new possibilities for developing precision cancer treatments by selectively eliminating disease-causing proteins, including proteins once considered undruggable.
“While more than 600 E3 ligases exist in the human proteome, we have utilized only a few so far, such as VHL and cereblon, for TPD,” said Weiru Wang, Executive Director of Protein Sciences and Structural Biology and lead study author at Frontier Medicines. “Demonstrating that DCAF2 can be harnessed for this purpose is a major step forward for protein degradation, and for Frontier, as it aligns with our mission to unlock new ways to fight cancer and drug the undruggables. This is a compelling example of how our platform enables us to see more deeply into the proteome and develop novel ways to hit difficult targets.”
The study leveraged the Frontier™ Platform, as well as advanced cryogenic electron microscopy, to present the first reported structures of the DCAF2 complex in both its apo and liganded state. The team discovered DCAF2 can covalently and selectively bind to small molecules and cause the degradation of other proteins, opening up a novel target site for TPD and a new avenue for the development of therapeutic bifunctional degraders and molecular glues that leverage DCAF2.
About Frontier Medicines
Frontier Medicines is a clinical-stage precision medicine company pioneering groundbreaking medicines to transform treatment for genetically defined patient populations, initially focusing on oncology and immunology. Our proprietary chemoproteomics-powered drug discovery engine, the Frontier™ Platform, leverages covalent chemistry and machine learning to unlock difficult-to-drug disease-causing proteins for drug development. Today, we are advancing a diversified pipeline of wholly owned precision medicines against the most critical drivers of cancer and high-value immunology programs. For more information, please visit www.frontiermeds.com. Follow Frontier on LinkedIn.
Media Contact
Cory Tromblee, Scient PR
cory@scientpr.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
